A specific serum lipid signature characterizes patients with glycogen storage disease type Ia

被引：1

作者：

Rossi, Alessandro ^{[1
,2
]}

Ruoppolo, Margherita ^{[3
,4
]}

Fedele, Roberta ^{[4
]}

Pirozzi, Francesca ^{[3
]}

Rosano, Carmen ^{[1
]}

Auricchio, Renata ^{[1
]}

Melis, Daniela ^{[5
]}

Strisciuglio, Pietro ^{[1
]}

Oosterveer, Maaike H. ^{[6
]}

Derks, Terry G. J. ^{[2
]}

Parenti, Giancarlo ^{[1
,7
]}

Caterino, Marianna ^{[3
,4
]}

机构：

[1] Univ Naples Federico II, Dept Translat Med, Sect Pediat, Naples, Italy

[2] Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, Sect Metab Dis, Groningen, Netherlands

[3] Univ Naples Federico II, Dept Mol Med & Med Biotechnol, Naples, Italy

[4] CEINGE Biotecnol Avanzate sc ar l, Naples, Italy

[5] Univ Salerno, Dept Med Surg & Dent Scuola Med Salernitana, Salerno, Italy

[6] Univ Groningen, Univ Med Ctr Groningen, Dept Pediat & Lab Med, Groningen, Netherlands

[7] Telethon Inst Genet & Med, Pozzuoli, Italy

来源：

JOURNAL OF LIPID RESEARCH | 2024年 / 65卷 / 10期

关键词：

hyperlipidemia; serum lipidome; ceramides; bile acids; lysophosphatidylcholine; HYPERLIPIDEMIA; LIPOGENESIS; MANAGEMENT; RESISTANCE;

D O I：

10.1016/j.jlr.2024.100651

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Glycogen storage disease type Ia (GSDIa) is a rare, inherited glucose-6-phosphatase-alpha (G6Pase-alpha) deficiency-induced carbohydrate metabolism disorder. Although hyperlipidemia is a hallmark of GSDI, the extent of lipid metabolism disruption remains incompletely understood. Lipidomic analysis was performed to characterize the serum lipidome in patients with GSDIa, by including age- and sex-matched healthy controls and age-matched hypercholesterolemic controls. Metabolic control and dietary information biochemical markers were obtained from patients with GSDIa. Patients with GSDIa showed higher total serum lysophosphatidylcholine (Fold Change, (FC) 2.2, P < 0.0001), acyl-acylphosphatidylcholine (FC 2.1, P < 0.0001), and ceramide (FC 2.4, P < 0.0001) levels and bile acid (FC 0.7, P < 0.001), acylcarnitines (FC 0.7, P < 0.001), and cholesterol esters (FC 1.0, P < 0.001) than those of healthy controls, and higher di(FC 1.1, P < 0.0001; FC 0.9, P < 0.01) and triacylglycerol (FC 6.3, P < 0.0001; FC 3.9, P < 0.01) levels than those of healthy controls and hypercholesterolemic subjects. Both total cholesterol and triglyceride values correlated with Cer (d16:1/ 22:0), Cer (d18:1/20:0), Cer (d18:1/20:0(OH)), Cer (d18:1/ 22:0), Cer (d18:1/23:0), Cer (d18:1/24:1), Cer (d18:2/22:0), Cer (d18:2/24:1). Total cholesterol also correlated with Cer (d18:1/24:0), Cer (d18:2/20:0), HexCer (d16:1/22:0), HexCer (d18:1/18:0), and Hex2Cer (d18:1/20:0). Triglyceridelevels correlated with Cer (d18:0/24:1). Alanine aminotransferase values correlated with Cer (d18:0/ 22:0), insulin with Cer (d18:1/22:1) and Cer (d18:1/24:1), and HDL with hexosylceramide (HexCer) (d18:2/23:0). These results expand on the currently known involvement of lipid metabolism in GSDIa. Circulating Cer may allow for refined dietary assessment compared with traditional biomarkers. Because specific lipid species are relatively easy to assess, they represent potential novel biomarkers of GSDIa.

引用

页数：15

共 50 条

[21] Genotype and phenotype correlation in Korean patients with glycogen storage disease type IA
Ko, Jae Sung
Yang, Hye Ran
Seo, Jeong Kee
GASTROENTEROLOGY, 2006, 130 (04) : A803 - A803
[22] Antioxidative defence in pediatric patients with glycogen storage disease type IA and III
Ucar, Kalkan S.
Coker, M.
Sozmen, E.
Anik, A.
Simsek, Goksen R. D.
Darcan, S.
JOURNAL OF INHERITED METABOLIC DISEASE, 2008, 31 : 43 - 43
[23] Evaluation of central nervous system in patients with glycogen storage disease type IA
Gurakan, F.
Aydemir, Y.
Yuce, A.
Saltik-Temizel, I. N.
Demir, H.
Yalnizoglu, D.
Topcu, M.
Usta, Y.
Ozen, H.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2007, 44 : 163 - 163
[24] Stone Forming Risk Factors in Patients With Type Ia Glycogen Storage Disease
Scales, Charles D., Jr.
Chandrashekar, Aravind S.
Robinson, Marnie R.
Cantor, David A.
Sullivan, Jennifer
Haleblian, George E.
Leitao, Victor A.
Sur, Roger L.
Borawski, Kristy M.
Koeberl, Dwight
Kishnani, Priya S.
Preminger, Glenn M.
JOURNAL OF UROLOGY, 2010, 183 (03): : 1022 - 1025
[25] Bezafibrate induces autophagy and improves hepatic lipid metabolism in glycogen storage disease type Ia
Waskowicz, Lauren R.
Zhou, Jin
Landau, Dustin J.
Brooks, Elizabeth D.
Lim, Andrea
Yavarow, Zollie A.
Kudo, Tsubasa
Zhang, Haoyue
Wu, Yajun
Grant, Stuart
Young, Sarah P.
Huat, Bay Boon
Yen, Paul M.
Koeberl, Dwight D.
HUMAN MOLECULAR GENETICS, 2019, 28 (01) : 143 - 154
[26] Markedly elevated serum biotinidase activity may indicate glycogen storage disease type Ia
Wolf, B
Freehaud, CL
Thomas, JA
Gordon, PL
Greene, CL
Ward, JC
JOURNAL OF INHERITED METABOLIC DISEASE, 2003, 26 (08) : 805 - 809
[27] A pediatric patient with glycogen storage disease type IA and Castleman disease
Cuglievan, Branko
Menegaz, Brian A.
DePombo, April
Morani, Ajaykumar C.
Miranda, Roberto N.
Rytting, Michael
PEDIATRIC BLOOD & CANCER, 2017, 64 (08)
[28] High childhood serum triglyceride concentrations associate with hepatocellular adenoma development in patients with glycogen storage disease type Ia
Haring, Martijn P. D.
Peeks, Fabian
Oosterveer, Maaike H.
Brouwers, Martijn C. G. J.
Hollak, Carla E. M.
Janssen, Mirian C. H.
Langendonk, Janneke G.
Rennings, Alexander J. M.
Wagenmakers, Margreet A. E. M.
Verkade, Henkjan J.
Derks, Terry G. J.
de Meijer, Vincent E.
JHEP REPORTS, 2022, 4 (08)
[29] Activation of glycolysis and apoptosis in glycogen storage disease type Ia
Sun, Baodong
Li, Songtao
Yang, Liu
Damodaran, Tirupapuliyur
Desai, Dev
Diehl, Anna Mae
Alzate, Oscar
Koeberl, Dwight D.
MOLECULAR GENETICS AND METABOLISM, 2009, 97 (04) : 267 - 271
[30] Molecular prenatal diagnosis of glycogen storage disease type Ia
Qu, Y
Abdenur, JE
Eng, CM
Desnick, RJ
PRENATAL DIAGNOSIS, 1996, 16 (04) : 333 - 336

← 1 2 3 4 5 →